» Articles » PMID: 17020965

Gene Expression Profiling in Cervical Cancer: an Exploration of Intratumor Heterogeneity

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2006 Oct 6
PMID 17020965
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To explore intratumor heterogeneity in gene expression profiles from patients with cervical cancer.

Experimental Design: A total of 33 biopsies were obtained from 11 patients, sampling between two and five different areas for each tumor. The extracted RNA was hybridized onto the Affymetrix U133 Plus 2.0 oligonucleotide chip. The variance of expression within a patient (W), between patients (B) and the total variance (T = W + B) were calculated for each ProbeSet, and the ratio W/T was used as a measure of intratumor heterogeneity. Gene Ontology functional analysis was done to assess the function of genes that had high W/T (top 10%) and low W/T (bottom 10%) values.

Results: In total, 448 ProbeSets (2.2% of the total) had W/T < 0.10, indicating low intratumor heterogeneity, and 537 ProbeSets (2.7% of the total) had W/T > 0.90, indicating high intratumor heterogeneity. In total 14,473 ProbeSets (72.4%) had higher intertumor than intratumor heterogeneity (W/T < 0.5). Genes with low intratumor heterogeneity were characterized by a statistically significant enrichment of immune-related functions (P < 0.0001). Genes with high intratumor heterogeneity were characterized by a significant tendency towards nuclear localization and nucleic acid binding (both P < 0.0001). For genes with W/T > 0.5, more than six biopsies would be required to minimize the intratumoral heterogeneity to <0.15; if W/T is 0.3 to 0.4, four biopsies are required; and for low W/T of 0.16 to 0.3, only two to three biopsies would be needed.

Conclusion: Although the intratumor heterogeneity was low for the majority of the tested ProbeSets, for many genes, multiple biopsies are required to obtain a reliable estimate of gene expression.

Citing Articles

Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma.

Biswas D, Liu Y, Herrero J, Wu Y, Moore D, Karasaki T Nat Cancer. 2025; 6(1):86-101.

PMID: 39789179 PMC: 11779643. DOI: 10.1038/s43018-024-00883-1.


Bioinformatics Based Drug Repurposing Approach for Breast and Gynecological Cancers: Genes Address Common Hub Genes and Drugs.

Ayna Duran G Eur J Breast Health. 2025; 21(1):63-73.

PMID: 39744927 PMC: 11706122. DOI: 10.4274/ejbh.galenos.2024.2024-11-2.


Quantifying transcriptome diversity: a review.

Jones E, Haldar A, Oza V, Lasseigne B Brief Funct Genomics. 2023; 23(2):83-94.

PMID: 37225889 PMC: 11484519. DOI: 10.1093/bfgp/elad019.


Multi-region sequencing with spatial information enables accurate heterogeneity estimation and risk stratification in liver cancer.

Yang C, Zhang S, Cheng Z, Liu Z, Zhang L, Jiang K Genome Med. 2022; 14(1):142.

PMID: 36527145 PMC: 9758830. DOI: 10.1186/s13073-022-01143-6.


Cervical cancer heterogeneity: a constant battle against viruses and drugs.

Sun Q, Wang L, Zhang C, Hong Z, Han Z Biomark Res. 2022; 10(1):85.

PMID: 36397138 PMC: 9670454. DOI: 10.1186/s40364-022-00428-7.